What is ANAB's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.46B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ANAB?

P/E (TTM) is 7.44 and 52-week range is $20.18 to $72.36 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ANAB figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ANAB?

The company profile lists revenue (TTM) near $111M, net income (TTM) near $92M, EPS (TTM) near $3.34 when available from the market-data feed. Figures are informational and may lag live markets.

Where is AnaptysBio, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 29.9M shares outstanding, ISIN US0327241065 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

AnaptysBio, Inc.

$ANAB

Health Care · Biotechnology

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

AnaptysBio, Inc. is a clinical-stage biotechnology company, which engages in delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The company is headquartered in San Diego, California. The company went IPO on 2017-01-26. The firm manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The firm's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The firm's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).

Employees

104

Website

www.anaptysbio.com/

IPO

2017-01-26

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US0327241065

Headquarters

San Diego, California, US

Shares outstanding

29.9M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

106.45%

Browse other companiesFree AI scores and summaries for more stocks

AnaptysBio, Inc. (ANAB) Stock Analysis, Quote & Company Profile